Repligen (RGEN) Expected to Release Quarterly Earnings on Tuesday

Repligen (NASDAQ:RGEN) is expected to be announcing its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect the company to announce earnings of $0.46 per share and revenue of $201.5920 million for the quarter. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:00 AM ET.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.25 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same period last year, the firm posted $0.39 earnings per share. The business’s revenue was up 14.8% on a year-over-year basis. On average, analysts expect Repligen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Price Performance

NASDAQ RGEN opened at $131.96 on Friday. Repligen has a 12 month low of $100.99 and a 12 month high of $175.77. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The firm has a market capitalization of $7.44 billion, a PE ratio of 146.62, a P/E/G ratio of 2.54 and a beta of 1.06. The company’s 50 day simple moving average is $131.68 and its 200 day simple moving average is $132.60.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on RGEN shares. Benchmark upgraded Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research report on Tuesday, July 7th. Jefferies Financial Group reissued a “hold” rating and issued a $142.00 price objective on shares of Repligen in a research note on Tuesday, May 5th. Barclays boosted their price objective on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Royal Bank Of Canada assumed coverage on Repligen in a research note on Thursday, May 14th. They set an “outperform” rating and a $160.00 target price for the company. Finally, Citigroup raised Repligen to a “buy” rating in a report on Tuesday, July 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $165.36.

Insider Buying and Selling

In related news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the sale, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Measured Wealth Private Client Group LLC bought a new stake in shares of Repligen during the 3rd quarter worth $29,000. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen during the fourth quarter worth $36,000. Itau Unibanco Holding S.A. raised its position in shares of Repligen by 38.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 104 shares during the period. Johnson Financial Group Inc. purchased a new stake in shares of Repligen during the third quarter valued at $65,000. Finally, Wilmington Savings Fund Society FSB lifted its holdings in shares of Repligen by 2,750.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 495 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.